Royalty Pharma (RPRX) Net Income (2019 - 2026)
Royalty Pharma (RPRX) posted Net Income of $468.3 million for Q1 2026, up 31.56% sequentially from $355.9 million in Q4 2025, and up 7.79% YoY from $434.4 million in Q1 2025.
Royalty Pharma (RPRX) Net Income (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Net Income for 8 years, with the latest figure at $468.3 million in Q1 2026.
- Quarterly Net Income rose 7.79% year-over-year to $468.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 23.2% YoY) and the FY2025 annual result came in at $1.3 billion, changed 0.5% from the prior year.
- Net Income improved to $468.3 million in Q1 2026 per RPRX's latest filing, from $355.9 million in the prior quarter.
- Over five years, Net Income peaked at $806.4 million in Q3 2024 and troughed at -$610.0 million in Q4 2022.
- A 5-year average of $297.3 million and a median of $351.3 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income plunged 1236.61% in 2022, then surged 10266.93% in 2025.
- Over 5 years, Net Income stood at -$610.0 million in 2022, then soared by 217.63% to $717.6 million in 2023, then sank by 53.41% to $334.4 million in 2024, then gained by 6.45% to $355.9 million in 2025, then surged by 31.56% to $468.3 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered $468.3 million, $355.9 million, and $444.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.49 Mn |
| Mar 31, 2026 | 468.26 Mn |
| Dec 31, 2025 | 355.91 Mn |
| Sep 30, 2025 | 444.21 Mn |
| Jun 30, 2025 | 90.64 Mn |
| Mar 31, 2025 | 434.43 Mn |
| Dec 31, 2024 | 334.35 Mn |
| Sep 30, 2024 | 806.36 Mn |
| Jun 30, 2024 | 194.38 Mn |
| Mar 31, 2024 | -4.27 Mn |
| Dec 31, 2023 | 717.59 Mn |
| Sep 30, 2023 | 122.08 Mn |
| Jun 30, 2023 | 351.34 Mn |
| Mar 31, 2023 | 509.09 Mn |
| Dec 31, 2022 | -610.03 Mn |
| Sep 30, 2022 | 220.41 Mn |
| Jun 30, 2022 | 491.60 Mn |
| Mar 31, 2022 | 128.08 Mn |
| Dec 31, 2021 | 53.67 Mn |
| Sep 30, 2021 | 221.80 Mn |